Anything ‘Special’ in this report?

| Updated on May 05, 2018

The contentious Special 301 report where the US rates its trading partners on their IP (intellectual property) track record is slated to come out by the end of April. As much as countries try to play it down as a report reflecting the US perspective, trade associations and lobby groups take a serious note of the report as it provides them ammunition to elbow their way into other markets during trade negotiations. India does not get a favourable report due to efforts taken to keep medicines affordable for the local population. And that includes an amended Patent Law that does not allow patents on changes made to an existing drug, unless it shows greater efficacy. This year’s report too will be watched by the domestic pharma industry as it will reflect the thinking of the Trump administration.

Published on April 27, 2018

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor